Back to Agendas
[V5-S6] Industrial Development and Growth Strategy for Biosimilars - From the Viewpoint of the Acceleratation of Biosimilars Use
Session Chair(s)
Teruyo Arato, PhD
Professor, Clinical Research and Medical Innovation Center
Hokkaido University Hospital, Japan
The guidelines for quality/efficacy/safety of biosimilars and its Q and A have been issued in Japan, and currently biosimilar products have been approved in Japan. Expectations for industrial development for biosimilars will be much higher in the future. This session will cover how to change the Japanese medical environment by using biosimilar products and how to accelerate the use of biosimilars, as well as how to the grow industry of biosimilars in Japan. In this session, speakers from a pharmaceutical industry and academia will give a presentation about current environment and issues of the acceleration of biosimilars use. We will have a panel discussion with the above speakers and a panelist from a department of pharmacy in a hospital, who will talk about biosimilars use in a pharmacy point of view.
Speaker(s)
Launching Experiences of Biosimilars and Issues for Wider Use
Tetsuji Tsukamoto, MBA
Nippon Kayaku Co., Ltd., Japan
Head of Pharmaceutical Development Division,Pharmaceuticals Development Division
Biosimilar: Learnings from Nearly 10 Years of Real World Experience
Sreedhar Sagi, PhD
Sandoz Biopharmaceuticals, Germany
Head Medical Affairs, APAC
Expectation for Biosimilar Insulin Products by Clinical Diabetologists
Yasuo Terauchi, MD, PhD
Graduate School of Medicine, Yokohama City University, Japan
Professor, Endocrinology & Metabolism
Keiso Masuhara
St. Marianna University School of Medicine Hospital, Japan
Department of Pharmacy
Have an account?